A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma
Authors
Keywords
-
Journal
LEUKEMIA
Volume 26, Issue 7, Pages 1675-1680
Publisher
Springer Nature
Online
2012-02-22
DOI
10.1038/leu.2012.51
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial
- (2011) A. J. Jakubowiak et al. BLOOD
- Approach to the treatment of multiple myeloma: a clash of philosophies
- (2011) S. V. Rajkumar et al. BLOOD
- A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients
- (2011) James R. Berenson et al. BRITISH JOURNAL OF HAEMATOLOGY
- A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma
- (2010) Gabriel N. Waterman et al. ANNALS OF HEMATOLOGY
- Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma
- (2010) C. B. Reeder et al. BLOOD
- Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)
- (2010) J. A. Zonder et al. BLOOD
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
- (2010) P. G. Richardson et al. BLOOD
- Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features
- (2010) S. Kumar et al. BLOOD
- Rapid control of previously untreated multiple myeloma with bortezomib–lenalidomide–dexamethasone (BLD)
- (2010) M. Wang et al. Hematology
- Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study
- (2010) S K Kumar et al. LEUKEMIA
- Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma
- (2009) Niels W.C.J. van de Donk et al. BRITISH JOURNAL OF HAEMATOLOGY
- Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
- (2009) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Combination Therapy With Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Myeloma
- (2009) Andrzej J. Jakubowiak et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
- (2009) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Multiple myeloma: management of adverse events
- (2009) F. Gay et al. MEDICAL ONCOLOGY
- Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up
- (2008) James R. Berenson et al. ANNALS OF HEMATOLOGY
- Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
- (2008) M. Wang et al. BLOOD
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started